Morpheus III

Exclusively from Molecular Dimensions, the new Morpheus® III screen uniquely contains a range of small, drug-like compounds to aid protein stabilisation and crystallisation. Read below about how Morpheus III and it’s rational screening methodology can help your screening efforts by expanding the range of chemical space your screen. The Morpheus III screen was developed at the MRC-LMB, Cambridge, UK and exclusively licensed to Molecular Dimensions by LifeARC.

MORPHEUS III represented according to the standard 96-condition screen layout. The screen is a 3D grid composed of 8 additive mixes (dipeptides, vitamins, nucleosides etc.), 4 cryoprotecting precipitant mixes (e.g. PEG 4000 with glycerol) and 3 buffer systems (pH 6.5, 7.5 and 8.5).

Learn More About This Product
SKU: M-MD1-116$2,562.00
SKU: M-MD1-117$824.00
SKU: M-MD1-118$219.00
SKU: M-MD1-123$4,578.00
SKU: M-MD1-124$1,372.00

Product Information

Cure your screening problems with the drug-like additives in Morpheus III

  • The screen increases the chances of a hit by expanding the amount of chemical space screened with 44 small drug-like compounds including phytochemicals, antibiotics, cholic acid derivatives and vitamins.
  • Unique to Morpheus III, these compounds aid crystallisation, as they can be protein-stabilising and are often found in structures in the PDB.
  • Morpheus III is not biased towards particular macromolecules or reagents as it was designed de novo and optimised against a broad range of protein samples.
  • Hits can be easily optimised with the Hippocrates™(M-MD1-118) additive screen which contains all 44 drug-like compounds used in Morpheus III (see this webinar for advice about optimising Morpheus conditions).
  • The novel chemical space is systematically explored with a 3D grid, utilising 8 additive mixes, 4 cryoprotected precipitant mixes and 3 buffer systems.

Morpheus III is the latest member of the Morpheus screen family developed by Dr Fabrice Gorrec of the MRC-LMB, Cambridge, UK. Dr Gorrec is the creator of a range of popular and novel screens including Morpheus and the LMB Crystallisation screen, all of which have successfully crystallised a number of challenging targets. Theoretical and pragmatic aspects are taken into account in the formulation of these screens from scratch, as described in a freely available webinar.